Home
Companies
Catalysts
Deep Dives
MARITIME-OSA-2
PHASE3
ACTIVE
Drug:
MariTide
·
AMGN
Study Design
Design
Randomized, double-blind, placebo-controlled
Duration
52 weeks
NCT
NCT07226765
Treatment Arms
MariTide
SC (dose TBD)
Placebo
Placebo SC
Primary Endpoints
[{"id":"ahi","name":"Change in AHI","type":"PRIMARY","results":[],"description":"AHI in OSA patients NOT on PAP therapy. 52-week treatment period."}]
Assessment
Recruiting since Nov 2025. Patients NOT on PAP. 52 weeks. Source: ClinicalTrials.gov NCT07226765
Background & Context
Companion to MARITIME-OSA-1 in patients NOT using CPAP. Addresses broader population.
Data from Supabase · Updated 2026-03-24